May 1, 2015
Renowned Diabetologist and Former Chairman of ADA Primary Care Advisory Group joins Glytec Executive Team
Dr. Andrew S. Rhinehart to serve as Chief Medical Officer of Glytec.
Greenville, SC — Glytec, a clinical information technology company dedicated to improving insulin management and glycemic control for patients in hospitals and other care settings, today announced that Andrew S. Rhinehart, MD, FACP, CDE, BC-ADM, CDTC, has joined the company as chief medical officer. In this role, Rhinehart will leverage his 20 years of clinical expertise to aid the development and innovation of Glytec’s suite of computerized, predictive dosing algorithms for IV, subcutaneous and pediatric insulin dosing.
Prior to joining Glytec, Rhinehart served as a diabetologist and program director of the Johnston Memorial Diabetes Care Center and Johnston Memorial Center for Comprehensive Wound Care in Abingdon, Virginia. He also served as physician champion for the Inpatient Glycemic Control Initiative at Mountain States Health Alliance, the region’s largest healthcare system serving 29 counties in Tennessee, Virginia, Kentucky and North Carolina. Additionally, Rhinehart is an active member of the American Diabetes Association (ADA), having previously served as chairman of its Primary Care Advisory Group. Rhinehart was also the first physician to be board certified in advanced diabetes management (BC-ADM) by the American Association of Diabetes Educators.
“The decision to leave clinical practice after 20 years was difficult, but in the end it came down to one thing — believing in Glytec as the right solution,” said Rhinehart. “After spearheading an inpatient glycemic control program for a large health system and implementing Glytec’s solution across the system, it became clear to me that this is the solution healthcare needs and patients deserve. Instead of helping 20-30 people with diabetes every day, joining Glytec gives me an opportunity to help thousands upon thousands of people with diabetes.”
As chief medical officer, Rhinehart will provide medical oversight and scientific leadership to ensure the delivery of innovative solutions that will improve and standardize glycemic management across the continuum of care. He is responsible for leading Glytec’s clinical strategy as well as providing expert guidance to key internal stakeholders, including scientific staff across multifunctional groups and external stakeholders, key opinion leaders and investors.
“Andrew will be an integral addition to the Glytec team and we are very excited to have him join us,” said Bob Leonard, CEO of Glytec. “His clinical expertise and passion for improving glycemic management will be invaluable to continuing the advancement of Glytec’s product development and scientific research as we uphold our mission to reduce the frequency, risk and costs related to hyper- and hypoglycemia.”
The Glytec solution– the eGlycemic Management System (eGMS®) — has evolved from an IV insulin dosing tool to a comprehensive, integrated glycemic management and surveillance system. The cloud-based system seamlessly integrates with leading electronic health records to improve workflow and nursing efficiency. Also included in the eGMS® are advanced clinical and business intelligence analytics and real-time surveillance capabilities.